SCCS Revision of the Scientific Opinion on Vitamin A
Ingredients: RETINOL, RETINYL PALMITATE, RETINYL ACETATE, RETINYL LINOLEATE, RETINAL

Date of publication: 25/10/2022

The Scientific Committee on Consumer Safety has issued a final version of the Scientific Opinion on Vitamin A, concluding that exposure to Vitamin A derived from cosmetics can be a concern for higher exposure consumers, and since cosmetics alone do not exceed the upper limit the SCCS cannot suggest maximum concentration limits that take into account contributions from other sources.
Picture of Filipa Ferreira

Filipa Ferreira

Linkedin Instagram Facebook Address-card

BACKGROUND

Vitamin A is a group of lipid-soluble compounds that includes Retinol, Retinyl Palmitate, Retinyl Acetate, Retinyl Linoleate and Retinal. This vitamin is an essential micronutrient for most mammalian species, taking part in vision, immunity and embryo development, among others. Retinol (CAS number: 68-26-8 /11103-57-4), Retinyl Palmitate (CAS number: 79-81-2) and Retinyl Acetate (1CAS number: 27-47-9) are used as skin conditioning agents in cosmetics and personal care products.

In 2016, the European Commission’s Scientific Committee on Consumer Safety (SCCS) issued an opinion on Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate). The teratogenic potential of Vitamin A and effects on liver and skin were considered the most critical toxicological endpoints. The SCCS concluded that Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) at a maximum concentration of 0.05% (of retinol equivalent, RE) in body lotions is per se safe. The SCCS also considered that Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) at a maximum concentration of 0.3% RE for example in hand cream, face cream and leave-on and rinse-off products per se is safe. Simultaneously, baby skin care products, like body lotions and creams, containing Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) were considered safe for 1–3-year-old children. However, the cumulative exposure to Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) from sunscreen products, derivatives of Retinyl Linoleate and Retinal, exposure from sources other than cosmetic products, were not included in the SCCS opinion. Yet, the SCCS recognized that population’s overall exposure to Vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate) can be significantly higher, especially because the most important source of Vitamin A is usually diet (followed by supplements and cosmetics).

WHAT’S NEW?

After novel toxicological data regarding aggregated exposure to Vitamin A from cosmetics, diet and supplementation, and the contribution of cosmetic Vitamin A to the overall exposure to Vitamin A, the SCCS issued a revision of the opinion on October 2022. The SCCS concluded the following:

  • Regarding the contribution of cosmetic products to the overall/total exposure to Vitamin A, the SCCS considers that there are inconsistencies in model calculations. The probabilistic assessment regarding the contribution from food and food supplements shows that the exposure to Vitamin A of the most exposed consumers (5% of the total population) may already exceed the upper limit. Compared to food, the contribution of Vitamin A from cosmetics is lower. However, this can be a concern for consumers with highest exposure (5% of the total population) to vitamin A derived already derived from food and food supplements.
  • Regarding the updating of the maximum concentration limit for the different categories of cosmetic ingredients, the SCCS considers that cosmetics alone do not exceed the upper limit imposed for exposure to Vitamin A and contribution of different exposure sources is a risk management issue and cannot be addressed at the level of risk assessment. In this way, the SCCS cannot suggest maximum concentration limits that take into account contributions from other sources like food and food supplements.

References:

1. SCCS (Scientific Committee on Consumer Safety), revision of the scientific Opinion (SCCS/1576/16) on vitamin A (Retinol, Retinyl Acetate, Retinyl Palmitate), preliminary version of 10 December 2021, final version of 24-25 October 2022, SCCS/1639/21.

further
reading
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
Guilherme Semedo February 24, 2023
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
Guilherme Semedo February 15, 2023
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
Guilherme Semedo February 13, 2023
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
Guilherme Semedo January 9, 2023
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
Guilherme Semedo December 13, 2022
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
Liliana Teles December 10, 2022
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
Filipa Ferreira October 11, 2022
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
Filipa Ferreira October 4, 2022

services

CONTACT US

  • info@criticalcatalyst.com
  • +351 91 200 43 51
    PT mobile network call
  • EUROPEAN UNION (HQ)
    679 Avenida da República
    4450-242 Matosinhos (PT)
  • UNITED KINGDOM
    49 Queen Victoria Street
    EC4N 4SA London (UK)